List view / Grid view
2 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The approval is based on data from the phase 3b clinical trial, which examined the efficacy and safety of liraglutide versus placebo as an add-on to existing diabetes medication, to improve glycaemic control...
9 August 2016 | By Novo Nordisk
The drug was approved using evidence from three phase III studies in adults with type 1 diabetes mellitus and five phase III studies in adults with type 2 diabetes mellitus. The researchers discovered that insulin degludec was non-inferior to other long-acting insulin analogues, assessed by the mean change in glycosylated…
13 June 2016 | By Victoria White, Digital Content Producer
Novo Nordisk presented new findings from separate studies of Tresiba and semaglutide at the American Diabetes Association 76th Scientific Sessions...
3 June 2016 | By Victoria White, Digital Content Producer
Three-year data show early response to Novo Nordisk’s Saxenda (liraglutide 3 mg) resulted in improvements in weight loss and cardiometabolic risk factors...
31 May 2016 | By Victoria White, Digital Content Producer
Reputation Institute has announced that AbbVie, Sanofi and Novo Nordisk top the RepTrak ranking of the most reputable pharmaceutical companies in the UK...
28 April 2016 | By Victoria White, Digital Content Producer
The double-blinded SUSTAIN6 trial investigated the long-term cardiovascular and other safety outcomes of 0.5 mg and 1.0 mg semaglutide compared with placebo...
21 April 2016 | By Victoria White, Digital Content Producer
Novo Nordisk has announced that it plans to invest more than 100 million euros in production facilities at its site in Chartres, France...
5 April 2016 | By Victoria White
In a three year trial, individuals treated with Saxenda lost more weight (6.1%) than those treated with placebo (1.9%)...
2 April 2016 | By Victoria White
Semaglutide significantly improved glycaemic control compared to placebo in adults with type 2 diabetes previously managed with diet and exercise alone...
4 March 2016 | By Victoria White
Victoza (liraglutide) was studied over a period of up to 5 years in more than 9,000 adults with type 2 diabetes at high risk of major adverse cardiovascular events...
3 March 2016 | By Victoria White
New findings show that Xultophy is cost-effective versus current insulin intensification treatment options for the treatment of people in the UK with type 2 diabetes...
29 January 2016 | By Victoria White
SWITCH 2 is the first of two trials comparing the safety and efficacy of Tresiba (insulin degludec) and insulin glargine in patients with type 2 diabetes...
17 December 2015 | By Victoria White
The trial investigated the efficacy and safety of semaglutide compared with sitagliptin after 56 weeks of treatment in people with type 2 diabetes...
10 December 2015 | By Victoria White
Faster-acting insulin aspar is an investigational mealtime insulin developed by Novo Nordisk for the control of blood sugar levels in adults with type 1 and type 2 diabetes...
4 December 2015 | By Victoria White
Faster-acting insulin aspart is a mealtime insulin for improved control of postprandial glucose excursions and has been developed for the treatment of people with type 1 and type 2 diabetes...
